Proteasome inhibitor clioquinol as a candidate drug in prophylaxis and treatment of acute graft-versus-host disease
Authors:
- 30 November 2010
- journal article
- Published by Elsevier in Medical Hypotheses
- Vol. 76 (3) , 400-402
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Clinical development of novel proteasome inhibitors for cancer treatmentExpert Opinion on Investigational Drugs, 2009
- Graft-versus-host diseaseThe Lancet, 2009
- The toxicology of Clioquinol☆Toxicology Letters, 2008
- Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myelomaLeukemia, 2008
- Graft-versus-host diseaseNature Reviews Immunology, 2007
- Immunobiology of Allogeneic Hematopoietic Stem Cell TransplantationAnnual Review of Immunology, 2007
- Clioquinol, a Therapeutic Agent for Alzheimer's Disease, Has Proteasome-Inhibitory, Androgen Receptor–Suppressing, Apoptosis-Inducing, and Antitumor Activities in Human Prostate Cancer Cells and XenograftsCancer Research, 2007
- Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activationBlood, 2006
- Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokinesBlood, 2006
- RELATION BETWEEN SUBACUTE MYELO-OPTIC NEUROPATHY (S.M.O.N.) AND CLIOQUINOL: NATIONWIDE SURVEYThe Lancet, 1973